A laboratory test for glycated hemoglobin (HbA1c) is recommended for monitoring diabetic patients. It helps physicians understand how well the patient's diabetes is being managed from a treatment or dosing viewpoint.

A fully automated chemiluminescent microparticle immunoassay (CMIA), the Architect HbA1c assay helps laboratories manage the increased demand for diabetes management and provides a result to the physician in 36 minutes. It also demonstrates a good correlation to the gold standard (high performance liquid chromatography), which provides confidence in the accuracy and reproducibility of patient results.

The patient-administered blood glucose test takes a snapshot of a patient's blood sugar level at a moment in time. HbA1c is a form of hemoglobin used primarily to monitor long-term diabetes control. The HbA1c test must be performed on a laboratory instrument. It is used for the quantitative determination of percent hemoglobin A1c (HbA1c) in human whole blood on the Architect i System.

The Architect HbA1c assay helps laboratories manage the increased demand due to the rise in patients with diabetes and offers rapid results to physicians. The new assay is performed on the Architect immunoassay systems and is available in several European countries, Asia Pacific, Latin America, Japan, Africa, Middle East, and India, pending country registration.

Abbott (Abbott Park, IL, USA) has developed and launched a series of Architect analyzers that are flexible, automated, and convenient. Architect offers more than 170 assays and has features that minimize training and reduce inventory costs and sample contamination potential, which results in improved performance and outcomes for laboratories, physicians, and patients. The new assay has received CE marking.

Related Links:
Abbott